Amicus Therapeutics Inc. (NASDAQ:FOLD) finished Wednesday with an addition of $0.26 to close at $11.79, an upside of 2.25 percent. An average of 1,380,980 shares of common stock have been traded in the last five days. There was a gain of $0.07 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 1,914,650 shares traded, while the 50-day average volume stands at 2,287,970.
FOLD stock has increased by 2.25% in the last month. The company shares reached their 1-month lowest point of $11.42 on 11/29/22. With the stock rallying to its 52-week high on 08/25/22, shares of the company touched a low of $5.91 and a high of $12.96 in 52 weeks. It has reached a new high 8 times so far this year and achieved 2.08% or $0.24 in price. In spite of this, the price is down -9.03% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
FOLD stock investors should be aware that Amicus Therapeutics Inc. (FOLD) stock had its last reported insider trading activity 14 days ago on Dec 15. In this transaction, the insider spent $127,172. Executive Chairman, Crowley John F, disposed of 11,347 shares at a price of $12.20 on Dec 01. The insider now owns more than $138,473 worth of shares. Prior to that, President & CEO Campbell Bradley L went on to Sale 5,485 shares at $12.20 each on Dec 01. An amount of $66,926 was transacted.
Amicus Therapeutics Inc. (FOLD) stock’s beta is 0.88. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 10.46, the price-to-book (PB) ratio at 25.63.
The quick ratio of Amicus Therapeutics Inc. for the three months ended June 29 was 2.70, and the current ratio was 2.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.95 and a total debt to equity ratio of 2.95 for the quarter ending June 29. Its gross profit as reported stood at $271.05 million compared to revenue of $305.51 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Amicus Therapeutics Inc.’s return on assets was -32.10%.
For the three-month period that ended June 29, Amicus Therapeutics Inc. had $77.11 million in cash and short-term investments compared to $391.32 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$33.29 million in the quarter, while revenues of -$62.16 million were shrunk -51.07%. The analyst consensus anticipated Amicus Therapeutics Inc.’s latest quarter earnings to come in at -$0.22 per share, but it turned out to be -$0.21, a 4.50% surprise. For the quarter, EBITDA amounted to -$31.89 million. Shareholders own equity worth $280.94 million.
From a technical analysis perspective, let’s take a brief look at Amicus Therapeutics Inc. (FOLD) price momentum. RSI 9-day as of the close on 28 December was 48.17%, suggesting the stock is Neutral, with historical volatility in this time frame at 31.98%.
As of today, FOLD’s price is $11.77 +0.60% or $0.07 from its 5-day moving average. FOLD is currently trading +2.70% higher than its 20-day SMA and -3.20% lower than its 100-day SMA. However, the stock’s current price level is +7.28% above the SMA50 and +37.09% above the SMA200.
The stochastic %K and %D were 17.63% and 18.23%, respectively, and the average true range (ATR) was 0.44. With the 14-day stochastic at 29.81% and the average true range at 0.47, the RSI (14) stands at 50.52%. The stock has reached -0.19 on the 9-day MACD Oscillator while the 14-day reading was at -0.29.
Morgan Stanley launched coverage on Amicus Therapeutics Inc. (NASDAQ: FOLD) in its analyst report released on September 09, 2022. The firm assigned the stock an Equal-weight rating.
What is FOLD’s price target for the next 12 months?
Analysts predict a range of price targets between $10.00 and $20.00, with a median target of $15.00. Taking a look at these predictions, the average price target given by analysts for Amicus Therapeutics Inc. (FOLD) stock is $14.82.